Latest news
Loading news…
Axolotl Biologix
ActiveOperating status — whether the company still runs independently. “Closed” usually means it was acquired, merged, or shut down.🔥 LowHeat score — how much recent activity & attention the company has (web traffic, news, hiring). Phoenix, Arizona, United States Founded 2016 11-50 employees For Profit
Axolotl Biologix is a biotechnology firm focusing on producing regenerative medicine through research, technology & clinical application.
Axolotl Biologix was acquired by Carmell Cosmetics in 2023 for $65M.
Total Funding
Available in Pro Last Funding
Available in Pro Acquisitions
1
Monthly Visits
Available in Pro Contacts
11
Patents
1
6 trademarks
Company Details
Funding & Financials
Pro- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
IPO & Stock
- IPO status
- Private
Web Traffic
Pro- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Technology & IP
- Active technologies
- 24
- Active products
- 8
- Patents granted
- 1
- Trademarks
- 6
- Top patent class
- Medical Or Veterinary Science; Hygiene
- IT spend
- $130K
Company Info
- Founded
- 2016
- Employees
- 11-50
- Operating status
- Active
- Company type
- For Profit
- Org types
- company
- News articles
- 15
- HQ
- Phoenix, Arizona, United States
- Region
- Greater Phoenix Area, Western US
- Exit date
- Jul 27, 2023
Signals & Scores
- Heat score
- Low
- Trend (7d)
- 1.5
- Trend (30d)
- -0.8
- Trend (90d)
- -0.9
Acquisitions by Axolotl Biologix
Loading columns…
0 of 0Show
Page 1 / 1
11
professional contacts at Axolotl Biologix
Contact execs at Axolotl Biologix →Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Recent News related to Axolotl Biologix
Loading news…
FAQs about Axolotl Biologix
People who checked this page also checked these
Browse the full Acquirezy directory.